January 13, 2026/
This document details the safety signals reviewed and the regulatory actions recommended by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) during its meeting in November 2025.
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
This document details the safety signals reviewed and the regulatory actions recommended by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) during its meeting in November 2025.
On January 5, 2026, the landscape of weight management in America shifted with the broad availability of Novo Nordisk's Wegovy® (semaglutide) pill. As the first and only...
A new international study protocol, published by the World Health Organization (WHO) in 2025, lays the groundwork for a critical public health initiative: determining how often...
